このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease

2026年11月13日 更新者:Centre Hospitalier Universitaire de Nice

Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease: An Observational Study of the Relationships Between CMTES-v2, Nerve Conduction Parameters, and Functional Capacity

CMT-PROFILE is a single-center, cross-sectional observational study involving adults with Charcot-Marie-Tooth disease (CMT). The study will investigate the association between clinical disease severity, measured using the CMT Examination Score version 2 (CMTES-v2), and motor electrophysiological parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities. Secondary objectives include characterizing clinical-electrophysiological concordance, comparing functional capacity, muscle strength and mobility across concordance groups, and exploring demographic, clinical, biological and genetic factors associated with variability in disease expression. Approximately 250 patients are planned for inclusion. All assessments will be performed at a single reference time point (M0), with no longitudinal follow-up.

調査の概要

研究の種類

観察的

入学 (推定)

250

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Alpes Maritimes
      • Nice、Alpes Maritimes、フランス、06000
        • CHU de Nice
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adults with Charcot-Marie-Tooth disease evaluated at the Peripheral Neuromuscular Rare Disease Reference Center of Nice University Hospital. The study aims to characterize the relationships between clinical disease severity, assessed using the CMTES-v2, motor electrophysiological parameters, and functional capacity. Participants will undergo a single reference assessment (M0), with no subsequent follow-up. The planned sample size is approximately 250 participants, subject to confirmation against the approved protocol.

説明

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Diagnosis of peripheral sensory polyneuropathy.
  • Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.
  • Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.
  • Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.

Exclusion Criteria:

  • Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.
  • Unclassifiable neuropathy phenotype.
  • Technical factors affecting the reliability of nerve conduction studies.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
介入・治療
Adults with Charcot-Marie-Tooth Disease

This observational, cross-sectional study evaluates clinical severity, electrophysiological parameters, and functional capacity in adults with Charcot-Marie-Tooth disease (CMT). Data collected at a single reference time point (M0) include the CMT Examination Score version 2 (CMTES-v2), nerve conduction study parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities, and available functional and clinical measures. Additional variables may include muscle strength, mobility, pain, patient-perceived disease severity, occupational impact, and demographic, clinical, and genetic characteristics, as specified in the study protocol. No study-specific treatment or intervention is administered. There is no longitudinal follow-up

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Association Between CMTES-v2 and Motor Electrophysiological Parameters
時間枠:At day 0 (single assessment; no follow-up).

To assess the association between the CMTES-v2 total score and prespecified motor electrophysiological parameters, including distal CMAP amplitudes and motor nerve conduction velocities, using correlation analyses as specified in the statistical analysis plan.

At day 0 (single assessment; no follow-up).

二次結果の測定

結果測定
メジャーの説明
時間枠
Clinical-Electrophysiological Concordance and Discordance Classification
時間枠:At Day 0 (single assessment; no follow-up).

disease severity and electrophysiological impairment, using standardized residuals derived from the difference between observed CMTES-v2 scores and scores predicted from motor electrophysiological parameters, divided by the residual standard deviation. Patients will be classified into three mutually exclusive categories: concordant (standardized residual between -1.96 and +1.96), greater clinical severity than predicted (standardized residual above +1.96), or lower clinical severity than predicted (standardized residual below -1.96). Results will be expressed as the number and percentage of patients in each category.

At Day 0 (single assessment; no follow-up).
Age at Assessment Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up)

To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Age at Symptom Onset Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up)

To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Disease Duration Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up)

To evaluate the relationship between disease duration and clinical-electrophysiological concordance, disease duration will be calculated as the interval, expressed in years, between the reported onset of symptoms and the reference clinical assessment. Disease duration will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Genetic Subtype Distribution Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up)

To investigate whether the distribution of genetically confirmed Charcot-Marie-Tooth disease subtypes differs according to clinical-electrophysiological concordance, genetic subtypes documented in the medical records will be categorized and compared across the three predefined concordance groups. Results will be reported as the number and percentage of patients within each genetic subtype among those with available genetic data.

At Day 0 (single assessment; no follow-up)
Functional Performance Across Clinical-Electrophysiological Concordance Groups (CMT-FOM)
時間枠:At Day 0 (single assessment; no follow-up).

To evaluate whether functional performance differs according to clinical-electrophysiological concordance, functional capacity will be quantified using the total score of the Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Scores will be compared across the three predefined concordance groups among patients with available assessments.

At Day 0 (single assessment; no follow-up).
Muscle Strength Across Clinical-Electrophysiological Concordance Groups (MRC Scale)
時間枠:At Day 0 (single assessment; no follow-up)

To assess differences in muscle strength according to clinical-electrophysiological concordance, muscle strength will be evaluated using the Medical Research Council (MRC) grading scale, ranging from 0 (no visible or palpable muscle contraction) to 5 (normal muscle strength). Recorded muscle strength grades will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Right Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up)

To assess differences in right handgrip strength according to clinical-electrophysiological concordance, right handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Left Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up).

To assess differences in left handgrip strength according to clinical-electrophysiological concordance, left handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up).
Functional Mobility Across Clinical-Electrophysiological Concordance Groups (Timed Up and Go)
時間枠:At Day 0 (single assessment; no follow-up)

To investigate differences in functional mobility according to clinical-electrophysiological concordance, mobility will be assessed using the Timed Up and Go (TUG) test, measuring the time required to rise from a chair, walk three meters, turn, return to the chair and sit down. Completion time will be recorded in seconds and compared across the three predefined concordance groups. Inability to complete the test safely will be recorded as a non-feasible assessment rather than assigned an arbitrary completion time.

At Day 0 (single assessment; no follow-up)
Pain Intensity Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up).

To investigate whether pain intensity differs according to clinical-electrophysiological concordance, average pain intensity over the preceding seven days will be assessed using an 11-point numerical rating scale, ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up).
Patient-Perceived Disease Severity Across Clinical-Electrophysiological Concordance Groups
時間枠:At Day 0 (single assessment; no follow-up)

To evaluate differences in patient-perceived disease severity according to clinical-electrophysiological concordance, overall disease severity will be self-rated using a five-point ordinal scale ranging from 1 (very mild) to 5 (very severe). Scores will be compared across the three predefined concordance groups.

At Day 0 (single assessment; no follow-up)
Work Absenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
時間枠:At Day 0 (single assessment; no follow-up)

To investigate differences in work absenteeism associated with Charcot-Marie-Tooth disease according to clinical-electrophysiological concordance, absenteeism will be assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) and quantified as the percentage of working time missed due to the disease during the preceding seven days, ranging from 0% to 100%. Comparisons will be performed across the three predefined concordance groups among employed participants for whom the measure is applicable.

At Day 0 (single assessment; no follow-up)
Work Presenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
時間枠:At Day 0 (single assessment; no follow-up).

To investigate differences in work-related productivity impairment while present at work according to clinical-electrophysiological concordance, presenteeism will be assessed using the WPAI:SHP questionnaire and expressed as the percentage of impairment while working attributable to Charcot-Marie-Tooth disease during the preceding seven days, ranging from 0% to 100%. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable.

At Day 0 (single assessment; no follow-up).
Overall Work Productivity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
時間枠:At Day 0 (single assessment; no follow-up).

To assess whether overall work productivity impairment differs according to clinical-electrophysiological concordance, overall impairment will be calculated from the absenteeism and presenteeism components of the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable

At Day 0 (single assessment; no follow-up).
Daily Activity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
時間枠:At Day 0 (single assessment; no follow-up)

To assess differences in the impact of Charcot-Marie-Tooth disease on usual daily activities according to clinical-electrophysiological concordance, activity impairment will be quantified using the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups, irrespective of employment status

At Day 0 (single assessment; no follow-up)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Angela Puma、Centre Hospitalier Universitaire de Nice

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2026年12月1日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2026年10月29日

QC基準を満たした最初の提出物

2026年11月13日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する